An innovative medicines company working to reimagine medicine. See our community guidelines: go.novartis.social/4bqbjuA.
United States
- Tweets 440
- Following 23
- Followers 2,828
- Likes 139
Discover what to expect from Novartis at @ACRheum Convergence 2026 as we continue to advance research and shape what’s next in rheumatic disease care. #ACR26 #rheumatology #immunology
79
#News: Novartis announces new Phase III data in relapsing #MultipleSclerosis (MS) at #MSToronto2026, reinforcing commitment to ongoing MS innovation. novartis.social/6012axXN0
1
144
#News: Novartis announces FDA approval for the first therapy for adults with symptomatic dermographism (SD), the most common form of chronic inducible urticaria (CIndU). Learn more: 🔗 novartis.social/6016ao5AI
2
144
#News: Novartis will present new data at #MSToronto2026, including two late-breaking abstracts, underscoring its broad portfolio and multiple sclerosis (#MS) innovation. novartis.social/6015aopdL
127
#News: FDA approval expands options for patients with metastatic androgen pathway modulation-naive/sensitive (mAPMN/S) prostate cancer.
Learn more about how treatment is evolving for the #ProstateCancer community.
🔗: novartis.social/6019aBnWJ
2
541
#News: Novartis announces FDA traditional approval of treatment for adults with primary IgA nephropathy (#IgAN) at risk of disease progression novartis.social/6019v27B7
2
8
1,658
#News: Novartis presents new data in chronic inducible urticaria (CIndU) at the European Academy of Allergy & Clinical Immunology Congress 2026.
Learn more: 🔗 novartis.social/6019v92zR
#EAACI2026
552
#News: Novartis presents data across multiple immune-mediated diseases at the European Academy of Allergy & Clinical Immunology Congress 2026.
Learn more: 🔗 go.novartis.social/4v0pPlU #EAACI2026
326
New Novartis data published today in @NEJM and presented at @eular_org 2026 address critical unmet need and offer renewed hope for people living with #PolymyalgiaRheumatica (#PMR) novartis.social/6018vjcFA
#NEJM #EULAR2026 #Rheumatology #Immunology #NovartisNews
218
Novartis to present new data on complex immune-mediated diseases #PolymyalgiaRheumatica (#PMR) and #SjögrensDisease at @eular_org 2026 Annual Congress novartis.social/6010vbHOm
#EULAR2026
199
Novartis US retweeted
#News #Novartis announces at 2026 ASCO® Annual Meeting that CML treatment continued to show superior efficacy and a favorable safety and tolerability profile at week 144 in newly diagnosed CML #ASCO26 novartis.social/6019vbGkh
1
4
452
Novartis US retweeted
#News: #Novartis announces new data from two clinical trials evaluating radioligand therapies at 2026 ASCO® Annual Meeting #ASCO26 novartis.social/6017vwWSH
1
2
506
#News: Novartis shares new data at #ASCO26 and #EHA26 highlighting RLT innovation and reinforcing leadership in prostate cancer, breast cancer and hematology. novartis.social/6019vVuV1
1
3
404
#News: We broke ground on our Denton, Texas, RLT manufacturing facility – our fifth RLT site in the US. A critical part of our $23 billion US investment in research and manufacturing, this milestone helps bring highly personalized cancer therapies closer to patients. 🔗 go.novartis.social/4u3xHTk
233
#News: Learn about our new facility plans in Morrisville, North Carolina. The new site will focus on active pharmaceutical ingredient (API) manufacturing. It's our seventh new facility added within a year of our announced $23 billion investment in the US: 🔗 bit.ly/4vRlORw
3
7
551
#News: Novartis showcases progress in autoimmune and immune-mediated diseases impacting the skin at the American Academy of Dermatology Annual Meeting #AAD2026.
Learn more:🔗 bit.ly/4uKJXZt
288
#News: Today’s FDA approval of a treatment for pediatric patients age 12+ with moderate to severe #HidradenitisSuppurativa (#HS) marks a major step forward for this patient population.
Learn more about how Novartis is pioneering change in Immunology:
🔗 bit.ly/47jEn6v
1
2
916
Eight in 10 breast cancer patients carry the fear of recurrence. Hear from survivor Brooklyn as she reflects on her breast cancer journey, including how she faced her anxieties about her cancer returning.
1
256
From advocating in DC with @ZEROCancer, to pioneering research at #ASCOGU26, prostate cancer care demands more than scientific breakthroughs. It requires education and partnership from coast to coast to support patients across their cancer journey. 🤝
1
2
251